PSNL

Hall Christopher M

Known title: President and CEOCIK: 0001449535

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 14, 2026

Competitors Tempus and Natera draw market attention. Recent news highlights increased activity by Personalis competitors. Tempus AI is expanding its cancer vaccine infrastructure with Moderna and Merck, while Natera faces rising competitive threats. These developments underscore the crowded nature of the precision medicine sector, providing context for Personalis's current trading position near its support levels.

this person other insiders at PSNL

Transaction History

PSNL▼ Sell$121K
PSNL▲ Buy$161K
PSNL▼ Sell$1.5M
PSNL▼ Sell$1.3M
PSNL▲ Buy$161K
PSNL▲ Buy$129K
PSNL▼ Sell$883K
PSNL▲ Buy$32K
PSNL▼ Sell$219K
PSNL▲ Buy$0
PSNL▼ Sell$266K
PSNL▼ Sell$142K
PSNL▼ Sell$19K

We use analytics to understand how market-wall is used. No personal data is sold.